A Study of LY3415244 in Participants With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2019-10-09
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety of LY3415244, a PD-L1/TIM-3 bispecific
antibody, administered as monotherapy to participants with advanced solid tumors.